Gilead Sciences reported additional data from the company’s Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
The death toll from COVID-19 surpassed half a million people, according to a Reuters tally, a grim milestone for the global pandemic that seems to be resurgent in some countries even as other regions are still grappling with the first wave.
The U.S. Food and Drug Administration granted clearance for Akili’s EndeavorRx as a prescription treatment for children with attention deficit hyperactivity disorder (ADHD).
The U.S. Food and Drug Administration approved a drug to treat infants and children with HIV, with the drug having been developed by drugmaker GlaxoSmithKline’s HIV drugs division ViiV Healthcare.
The National Institutes of Health (NIH) launched a study to evaluate drugs prescribed to treat COVID-19, the respiratory disease caused by the new coronavirus, among children and adolescents across the United States.
The U.S. Food and Drug Administration approved Dupixent (dupilumab) for children aged 6 to 11 years with moderate-to-severe atopic dermatitis.
Children have milder COVID-19 symptoms than adults and the balance of evidence suggests they may also have lower susceptibility and infectivity than adults, scientists advising the British government said.
Oxford University and AstraZeneca are recruiting around 10,000 adults and children in Britain for trials of an experimental coronavirus vaccine, a day after receiving U.S. backing worth up to $1.2 billion.
The U.S. Food and Drug Administration accepted a New Drug Application and two supplemental NDAs for Genentech’s Xofluza (baloxavir marboxil).
The U.S. Food and Drug Administration approved Gilead Sciences’ Epclusa for hepatitis C (HCV) for use in children as young as 6 years of age or who weigh at least 17 kilograms.